BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 32547647)

  • 1. Tivozanib in renal cell carcinoma: a new approach to previously treated disease.
    Salgia NJ; Zengin ZB; Pal SK
    Ther Adv Med Oncol; 2020; 12():1758835920923818. PubMed ID: 32547647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.
    Beckermann KE; Asnis-Alibozek AG; Atkins MB; Escudier B; Hutson TE; Kasturi V; McDermott DF; Pal SK; Porta C; Rini BI; Verzoni E
    Oncologist; 2024 Mar; 29(3):254-262. PubMed ID: 38262444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approval.
    Viray H; McDermott DF; Einstein DJ
    Expert Rev Anticancer Ther; 2022 Jul; 22(7):695-702. PubMed ID: 35698870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of tivozanib in advanced renal cell carcinoma therapy.
    Escudier B; Porta C; Eisen T; Belsey J; Gibson D; Morgan J; Motzer R
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1113-1124. PubMed ID: 30084668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tivozanib in the treatment of renal cell carcinoma.
    Hepgur M; Sadeghi S; Dorff TB; Quinn DI
    Biologics; 2013; 7():139-48. PubMed ID: 23788831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma.
    Cowey CL
    Drug Des Devel Ther; 2013; 7():519-27. PubMed ID: 23818763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tivozanib: status of development.
    Jamil MO; Hathaway A; Mehta A
    Curr Oncol Rep; 2015 Jun; 17(6):24. PubMed ID: 25895472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Status of Tivozanib in the Treatment of Patients With Advanced Renal Cell Carcinoma.
    Sakellakis M; Zakopoulou R
    Cureus; 2023 Mar; 15(3):e35675. PubMed ID: 37012938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3.
    Meza L; McDermott DF; Escudier B; Hutson TE; Porta C; Verzoni E; Atkins MB; Kasturi V; Pal SK; Rini B
    Oncologist; 2023 Mar; 28(3):e167-e170. PubMed ID: 36576430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tivozanib: A New Hope for Treating Renal Cell Carcinoma.
    Passi I; Billowria K; Kumar B; Chawla PA
    Anticancer Agents Med Chem; 2023; 23(5):562-570. PubMed ID: 35718972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma.
    Yalcin S; Lacin S
    Cancer Manag Res; 2019; 11():7779-7785. PubMed ID: 31496820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial.
    Mehta A; Sonpavde G; Escudier B
    Future Oncol; 2014 Aug; 10(11):1819-26. PubMed ID: 25325825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tivozanib: practical implications for renal cell carcinoma and other solid tumors.
    Berge EM; Bowles DW; Flaig TW; Lam ET; Jimeno A
    Drugs Today (Barc); 2013 May; 49(5):303-15. PubMed ID: 23724410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial.
    Barata PC; Chehrazi-Raffle A; Allman KD; Asnis-Alibozek A; Kasturi V; Pal SK
    Oncologist; 2023 Oct; 28(10):894-900. PubMed ID: 37315114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tivozanib for the treatment of metastatic renal cancer.
    Wong HH; Eisen T
    Expert Rev Anticancer Ther; 2013 Jun; 13(6):649-60. PubMed ID: 23773100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.
    Rini BI; Pal SK; Escudier BJ; Atkins MB; Hutson TE; Porta C; Verzoni E; Needle MN; McDermott DF
    Lancet Oncol; 2020 Jan; 21(1):95-104. PubMed ID: 31810797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study.
    Molina AM; Hutson TE; Nosov D; Tomczak P; Lipatov O; Sternberg CN; Motzer R; Eisen T
    Eur J Cancer; 2018 May; 94():87-94. PubMed ID: 29547835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.
    Motzer RJ; Nosov D; Eisen T; Bondarenko I; Lesovoy V; Lipatov O; Tomczak P; Lyulko O; Alyasova A; Harza M; Kogan M; Alekseev BY; Sternberg CN; Szczylik C; Cella D; Ivanescu C; Krivoshik A; Strahs A; Esteves B; Berkenblit A; Hutson TE
    J Clin Oncol; 2013 Oct; 31(30):3791-9. PubMed ID: 24019545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress and contrasts of the development of tivozanib for therapy of kidney cancer.
    Gupta S; Fishman M
    Expert Opin Pharmacother; 2011 Dec; 12(18):2915-22. PubMed ID: 22098229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma.
    Fishman MN; Srinivas S; Hauke RJ; Amato RJ; Esteves B; Cotreau MM; Strahs AL; Slichenmyer WJ; Bhargava P; Kabbinavar FF
    Eur J Cancer; 2013 Sep; 49(13):2841-50. PubMed ID: 23726267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.